Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) – Investment analysts at HC Wainwright dropped their Q4 2024 earnings per share estimates for Alimera Sciences in a research note issued to investors on Friday, May 19th. HC Wainwright analyst Y. Chen now anticipates that the biopharmaceutical company will earn $0.17 per share for the quarter, down from their previous forecast of $0.22. The consensus estimate for Alimera Sciences’ current full-year earnings is ($1.19) per share.
Several other research analysts have also commented on the stock. Craig Hallum decreased their price objective on shares of Alimera Sciences from $18.00 to $8.00 in a report on Monday, April 3rd. StockNews.com initiated coverage on shares of Alimera Sciences in a report on Tuesday, May 16th. They issued a “hold” rating for the company.
Alimera Sciences Trading Down 6.5 %
Insider Buying and Selling at Alimera Sciences
In other Alimera Sciences news, major shareholder Alto Investors Lp Palo sold 200,919 shares of the company’s stock in a transaction that occurred on Friday, March 24th. The shares were sold at an average price of $1.56, for a total transaction of $313,433.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Alimera Sciences news, Director Adam Morgan bought 1,401,901 shares of the business’s stock in a transaction that occurred on Wednesday, May 17th. The stock was purchased at an average price of $1.70 per share, for a total transaction of $2,383,231.70. Following the completion of the transaction, the director now owns 1,659,654 shares of the company’s stock, valued at approximately $2,821,411.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Alto Investors Lp Palo sold 200,919 shares of the stock in a transaction dated Friday, March 24th. The stock was sold at an average price of $1.56, for a total value of $313,433.64. The disclosure for this sale can be found here. 12.90% of the stock is owned by corporate insiders.
Institutional Trading of Alimera Sciences
Institutional investors and hedge funds have recently bought and sold shares of the stock. Millennium Management LLC purchased a new position in Alimera Sciences in the fourth quarter worth about $32,000. Susquehanna International Group LLP purchased a new position in Alimera Sciences in the fourth quarter worth about $92,000. Renaissance Technologies LLC boosted its stake in Alimera Sciences by 2.3% during the second quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock worth $698,000 after buying an additional 2,900 shares during the period. Finally, Caligan Partners LP purchased a new position in Alimera Sciences during the fourth quarter worth $1,297,000. 24.58% of the stock is currently owned by institutional investors.
About Alimera Sciences
Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Alimera Sciences (ALIM)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Alimera Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences and related companies with MarketBeat.com's FREE daily email newsletter.